North America

FDA Puts Alzheimer’s Prevention on the Trial Agenda
The FDA has launched a cross-centre neuroscience initiative whose first focus is Alzheimer’s prevention. It will examine whom prevention trials should enroll, what outcomes they should measure and what evidence can support a prevention claim.

Energy drinks went mainstream before their cardiac safety evidence did

HRR Testing Moves Upfront in Prostate Cancer

Cardiometabolic care is screening the pieces. It is not yet connecting them

FDA Redraws the TMB-High Treatment Line

Brown fat is looking less like a metabolic curiosity and more like a drug target

Enhertu Stumbles in Early Breast Cancer

Cardiometabolic screening is becoming a consumer product. Prevention is still a health-system job

Beans, lentils and chickpeas are linked to better metabolic health. America still barely eats them

Mango research exposes the limits of judging food by sugar alone
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
